Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Pulmonary/Respiratory Diseases
Disease Category: Asthma
Trial Information
A randomized, double-blind with open-lable active comparator, parallel group, multi-center study to evaluate the safety of once daily fluticasone furoate/XXX inhaled powder for 52 weeks in adult and adolescent subjects with asthma.
Individuals with asthma currently controlled with a moderate or high dose ICS with or without a contoller needed to establish a long term safety profile for a once daily inhalation powder.
Patient Inclusion Criteria:
- Individuals 12 and older with a diagnosis of asthma for at least 3 months using ICS for maintenance of asthma symptoms with or without a controller.
Patient Exclusion Criteria:
- Pregnancy, nursing or trying to become pregnant.
- Participation in a previous research study with this investigational product or in any study in the last 30 days.
- Milk protein allergy.
- Tobacco use within 3 months or a >/= 10 pack year history.
Dana Neilson, CCRC, Study Coordinator
Allergy Asthma Research Institute
333 Londonderry Drive, Suite #110
Waco, TX 76712
Phone: 254-751-1144, ext 232
Fax: 254-751-9922
EMail: dneilson@aactx.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
